Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy.
Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women.
Cardiac Energy Metabolism in Heart Failure.
Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED.
Circ Res. 2021 May 14;128(10):1487-1513. doi: 10.1161/CIRCRESAHA.121.318241. Epub 2021 May 13.
Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M, Li Y, Li S, Lv J.
Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.
Molecular mechanisms of diabetic cardiomyopathy.
Bugger H, Abel ED.
Diabetologia. 2014 Apr;57(4):660-71. doi: 10.1007/s00125-014-3171-6. Epub 2014 Jan 30.
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.
Park JJ.
Diabetes Metab J. 2021 Mar;45(2):146-157. doi: 10.4093/dmj.2020.0282. Epub 2021 Mar 25.
Oxidative stress and diabetic complications.
Giacco F, Brownlee M.
Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.
Guidelines on models of diabetic heart disease.
Heather LC, Hafstad AD, Halade GV, Harmancey R, Mellor KM, Mishra PK, Mulvihill EE, Nabben M, Nakamura M, Rider OJ, Ruiz M, Wende AR, Ussher JR.
Am J Physiol Heart Circ Physiol. 2022 Jul 1;323(1):H176-H200. doi: 10.1152/ajpheart.00058.2022. Epub 2022 Jun 3.
Nobiletin alleviates myocardial ischemia-reperfusion injury via ferroptosis in rats with type-2 diabetes mellitus.
Huang Q, Tian L, Zhang Y, Qiu Z, Lei S, Xia ZY.
Biomed Pharmacother. 2023 Jul;163:114795. doi: 10.1016/j.biopha.2023.114795. Epub 2023 May 3.
Mechanism of Ferroptosis and Its Role in Type 2 Diabetes Mellitus.
Sha W, Hu F, Xi Y, Chu Y, Bu S.
J Diabetes Res. 2021 Jun 28;2021:9999612. doi: 10.1155/2021/9999612. eCollection 2021.
Impact of peroxisome proliferator-activated receptor-alpha on diabetic cardiomyopathy.
Wang L, Cai Y, Jian L, Cheung CW, Zhang L, Xia Z.
Cardiovasc Diabetol. 2021 Jan 4;20(1):2. doi: 10.1186/s12933-020-01188-0.
Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy.
Knapp M, Tu X, Wu R.
Acta Pharmacol Sin. 2019 Jan;40(1):1-8. doi: 10.1038/s41401-018-0042-6. Epub 2018 Jun 4.
